Variable individual sensitivity to cannabis in patients with schizophrenia

International Journal of Neuropsychopharmacology

Volumn 13, Issue 9, 2010, Pages 1145-1154

  Goldberger, Céline ^a,b   Dervaux, Alain ^a,b   Gourion, David ^a,b   Bourdel, Marie Chantal ^a   Lǒo, Henri ^a,b   Laqueille, Xavier ^b   Krebs, Marie Odile ^a,b  

^a INSERM   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Brain maturation; cannabis; geneenvironment interaction; schizophrenia; vulnerability

Indexed keywords

CANNABIS;

ADULT; ARTICLE; DRUG SENSITIVITY; FAMILY HISTORY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PSYCHOGENESIS; PSYCHOSIS; SCHIZOPHRENIA;

AGE OF ONSET; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77957241382     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000647     Document Type: Article

References (54)

1. Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL (2008). Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Archives of General Psychiatry 65, 269-274.
2. Arndt S, Tyrrell G, Flaum M, Andreasen NC (1992). Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychological Medicine 22, 379-388.
3. Arseneault L, Cannon M, Poulton R, Murray R, et al. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 325, 1212-1213. (Pubitemid 35398785)
4. Arseneault L, Cannon M, Witton J, Murray RM (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 184, 110-117. (Pubitemid 38186851)
5. Baeza I, Graell M, Moreno D, Castro-Fornieles J, et al. (2009). Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophrenia Research 113, 129-137.
6. Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, et al. (2006). Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry 188, 237-242.
7. Beiser M, Erickson D, Fleming JA, Iacono WG (1993). Establishing the onset of psychotic illness. American Journal of Psychiatry 150, 1349-1354. (Pubitemid 23259569)
8. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. (2009). Modulation of mediotemporal and ventrostriatal function in humans by Delta9- tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of General Psychiatry 66, 442-451.
9. Bossong MG, van Berckel BN, Boellaard R, et al. (2009). 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34, 759-766.
10. Brunette MF, Mueser KT, Xie H, Drake RE (1997). Relationships between symptoms of schizophrenia and substance abuse. Journal of Nervous and Mental Disease 185, 13-20. (Pubitemid 27086590)
11. Bü hler B, Hambrecht M, Loffler W, an der Heiden W, et al. (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse. A retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research 54, 243-251.
12. Caspi A, Moffitt TE, Cannon M, McClay J, et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a generenvironment interaction. Biological Psychiatry 57, 1117-1127. (Pubitemid 40615773)
13. Compton MT, Whicker NE, Hochman KM (2007). Alcohol and cannabis use in urban, African American, first-episode schizophrenia-spectrum patients: associations with positive and negative symptoms. Journal of Clinical Psychiatry 68, 1939-1945.
14. Cougnard A, Marcelis M, Myin-Germeys I, De Graaf R, et al. (2007). Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis pronenesspersistence model. Psychological Medicine 37, 513-527. (Pubitemid 46359599)
15. DSouza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, et al. (2005). Delta-9- tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594-608.
16. DSouza DC, Sewell RA, Ranganathan M (2009). Cannabis and psychosis/schizophrenia: human studies. European Archives of Psychiatry and Clinical Neuroscience 259, 413-431.
17. DeLisi LE (1992). The significance of age at onset for schizophrenia. Schizophrenia Bulletin 18, 209-215.
18. Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, et al. (2003). Cannabis and schizophrenia: demographic and clinical correlates. Encephale 29, 11-17. (Pubitemid 36361972)
19. Erhenreich H, Rinn T, Kunert HJ, Moeller MR, et al. (1999). Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142, 295-301. (Pubitemid 29200157)
20. Green AI, Noordsy DL, Brunette MF, OKeefe C (2008). Substance abuse and schizophrenia: pharmacotherapeutic intervention. Journal of Substance Abuse Treatment 34, 61-71. (Pubitemid 350216350)
21. Green AI, Tohen MF, Hamer RM, Strakowski SM, et al. (2004). First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research 66, 125-135.
22. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health (Early Clinical Drug Evaluation Unit), US Department of Health, Education, and Welfare.
23. Henquet C, Di Forti M, Morrison P, et al. (2008). Gene-environment interplay between cannabis and psychosis. Schizophrenia Bulletin 34, 1111-1121.
24. Henquet C, Krabbendam L, Spauwen J, Kaplan C, et al. (2005a). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330, 11. (Pubitemid 40070467)
25. Henquet C, Murray R, Linszen D, van Os J (2005b). The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin 31, 608-612. (Pubitemid 41253312)
26. Hides L, Dawe S, Kavanagh DJ, Young RM (2006). Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. British Journal of Psychiatry 189, 137-143. (Pubitemid 44231272)
27. Johns A (2001). Psychiatric effects of cannabis. British Journal of Psychiatry 178, 116-122. (Pubitemid 32158073)
28. Jones SH, Thornicroft G, Coffey M, Dunn G (1995). A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). British Journal of Psychiatry 166, 654-659.
29. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276. (Pubitemid 18039085)
30. Krebs MO, Goldberger C, Dervaux A (2005). Cannabis use and schizophrenia. American Journal of Psychiatry 162, 401-402.
31. Larsen TK, Melle I, Auestad B, Friis S, et al. (2006). Substance abuse in first-episode non-affective psychosis. Schizophrenia Research 88, 55-62. (Pubitemid 44693253)
32. Leung A, Chue P (2000). Sex differences in schizophrenia, a review of the literature. Acta Psychiatrica Scandinavica 101, 3-38. (Pubitemid 30412890)
33. Mathers DC, Ghodse AH (1992). Cannabis and psychotic illness. British Journal of Psychiatry 161, 648-653.
34. May PR, Dencker SJ, Hubbard JW, Midha KK, et al. (1998). A systematic approach to treatment resistance in schizophrenic disorders. Treatment resistance. In: Dencker SJ, Kulhanel F (Eds), Treatment Resistance in Schizophrenia (pp. 22-23). Wiesbaden, Germany: Vieweg Verlag.
35. McGuire PK, Jones P, Harvey I, Williams M, et al. (1995). Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Research 15, 277-281.
36. Miller P, Lawrie SM, Hodges A, Clafferty R, et al. (2001). Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Social Psychiatry and Psychiatric Epidemiology 36, 338-342. (Pubitemid 32894736)
37. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328. (Pubitemid 47094993)
38. Murray RM, Morrison PD, Henquet C, Di Forti M (2007). Cannabis, the mind and society: the hash realities. Nature Reviews Neuroscience 11, 885-895. (Pubitemid 350006219)
39. NIMH Genetics Initiative (1992). Family Interview for Genetic Studies (FIGS). Rockville, MD, National Institute of Mental Health, 1992.
40. Nurnberger Jr. JI, Blehar MC, Kaufmann CA, York-Cooler C, et al. (1994). Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Archives of General Psychiatry 51, 849-859. (Pubitemid 24985906)
41. Pistis M, Perra S, Pillolla G, Melia M, et al. (2004). Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biological Psychiatry 56, 86-94. (Pubitemid 38849412)
42. Pope HG, Gruber AJ, Hudson JI, Cohane G, et al. (2003). Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug and Alcohol Dependence 69, 303-310. (Pubitemid 36293942)
43. Rais M, Cahn W Van Haren N, Schnack H, et al. (2008). Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. American Journal of Psychiatry 165, 490-496. (Pubitemid 351694292)
44. Scheller-Gilkey G, Thomas SM, Woolwine BJ, Miller AH (2002). Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophrenia Bulletin 28, 223-231. (Pubitemid 35462239)
45. Schlicker E, Kathmann M (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends in Pharmacological Sciences 22, 565-572. (Pubitemid 33042646)
46. Schneider M, Koch M (2003). Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28, 1760-1769. (Pubitemid 41070841)
47. Schneider M, Koch M (2005). Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 30, 944-957. (Pubitemid 40570910)
48. Selten JP, Veen N, Feller W, Blom JD, et al. (2001). Incidence of psychotic disorders in immigrant groups to The Netherlands. British Journal of Psychiatry 178, 367-372. (Pubitemid 32280932)
49. Van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, et al. (2002). Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology 156, 319-327. (Pubitemid 34857999)
50. Vanelle JM (1997). Refractory schizophrenia: historical and currently prevailing criteria and definitions. European Psychiatry 12 (Suppl. 5), 321s-326s.
51. Veen ND, Selten JP, van der Tweel I, Feller WG, et al. (2004). Cannabis use and age at onset of schizophrenia. American Journal of Psychiatry 161, 501-506. (Pubitemid 38326105)
52. Verdoux H, Sorbara F, Gindre C, Swendsen JD, et al. (2002). Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophrenia Research 59, 77-84. (Pubitemid 35284497)
53. Voruganti LN, Slomka P, Zabel P, Mattar A, et al. (2001). Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Research 107, 173-177. (Pubitemid 32868802)
54. Zammit S, Allebeck P, Andreasson S, Lundberg I, et al. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. British Medical Journal 325, 1199-1201. (Pubitemid 35398782)